Hepatic Steatosis, Liver Fibroses
Conditions
Brief summary
The goal of this study is to learn more about liver fibrosis and methods to detect it. We will evaluate and compare multiple MRI based measures of liver fibrosis in subjects with and without liver disease.
Detailed description
While liver biopsy is still considered the gold standard for diagnosing and assessing the presence and degree of liver fibrosis and inflammation, it has disadvantages including the potential for sampling error and risk of complications, including life-threatening bleeding. New imaging modalities such as MR Elastography, T1 mapping, T2 mapping, T1 rho, and magnetization transfer allow rapid, non-invasive evaluation of liver parenchymal characteristics and may be able to detect and quantify parenchymal fibrosis alleviating the need for biopsy. To date, the quantitative performance of these different techniques has not been extensively studied. This study is a single-center trial of non-invasive MR imaging techniques aimed at detecting and measuring liver fibrosis. Once optimized, these technologies may later be deployed in hypothesis driven research studies and/or routine clinical exams in the pediatric population here at CCHMC and/or as part of a multi-center study with specific IRB approval for that project. To assess the relative performance of each technique, correlation across techniques, and reproducibility across the range of fibrosis, 32 subjects will be enrolled in this preliminary study sub-divided into 4 groups (Group 1: Healthy/ Normal controls; Group 2: F1/F2 fibrosis as determined by prior biopsy (low grade fibrosis group); Group 3: F3/F4 fibrosis as determined by prior biopsy (high grade fibrosis group), Group 4: Hepatic steatosis with fibrosis (NAFLD group)). 8 healthy subjects without known or suspected liver disease will be enrolled as normal controls. 8 subjects each with known fibrosis based on liver biopsy within the last 6 months will be enrolled in Group 2 and Group 3 (total = 16). 8 subjects with known hepatic steatosis and liver fibrosis based on liver biopsy within the last 6 months will be enrolled in Group 4.
Interventions
DEVICEMRI
MRI scan performed on 1.5T Philips Ingenia MRI scanner.
Sponsors
Children's Hospital Medical Center, Cincinnati
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
8 Years to 21 Years
Healthy volunteers
Yes
Inclusion criteria
Group 1: 1. Healthy subjects with no known or suspected liver disease 2. Age 8 - 21 years Groups 2 and 3: 1. Biopsy confirmed liver fibrosis (F1/F2 Group 2, F3/F4 Group 3) 2. Age 8 - 21 years Group 4: 1. Biopsy confirmed hepatic steatosis AND biopsy confirmed liver fibrosis (any stage) 2. Age 8 - 21 years
Exclusion criteria
All subjects: 1. Subjects \<8 years of age and \>21 years of age. 2. BMI \> 35 kg/m2 3. Subjects deemed to possibly require sedation to undergo MR imaging 4. Inability to lie still for 90 minutes 5. Routine exclusions to MRI - e.g., implanted hardware 6. Pregnancy (verbal pregnancy screens - per standard practice in Radiology - will be administered to all female participants of child-bearing age at the time of enrollment and again immediately prior to imaging) 7. Prior history of liver transplantation Group 1 1. ALT ≥30 U/L 2. Clinical history or lab/biopsy results suggestive of the presence of liver disease including: steatosis, fibrosis, inflammation, tumor, etc. Group 2 and 3 1. Diagnosis of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis 2. Biopsy \>6 months prior to research MRI examination 3. Initiation of any medications (e.g. steroids, immunosuppressants, antivirals) or procedures (e.g. Kasai portoenterostomy) to treat the liver disease during the time between liver biopsy and study visit Group 4 1. Biopsy \>6 months prior to research MRI examination 2. Hepatic fat fraction \>5% 3. Substantial weight loss (\>10% of weight at time of biopsy) during the time between biopsy and study visit 4. Initiation of any medications to treat NAFLD (e.g. vitamin E) during the time between biopsy and study visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MR imaging vs. histologic scoring in hepatic fibrosis | 2 years | Correlate the results from the different imaging sequences designed to detect and quantify hepatic fibrosis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MRI reproducibility | 2 years | evaluate the reproducibility of each of the tested MRI-based liver fibrosis quantification sequences |
Countries
United States
Outcome results
None listed